Health CarePharmaceuticals & Biotechnology
  • Price (USD)125.88
  • Today's Change0.81 / 0.65%
  • Shares traded4.67m
  • 1 Year change+18.30%
  • Beta0.6847
Data delayed at least 15 minutes, as of Nov 26 2021 18:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.

  • Revenue in USD (TTM)42.31bn
  • Net income in USD7.27bn
  • Incorporated1900
  • Employees109.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttps://www.abbott.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABT:NYQ since
Walk Vascular LLCDeal completed02 Sep 202102 Sep 2021Deal completed-1.19%--
Data delayed at least 15 minutes, as of Nov 26 2021 18:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Align Technology, Inc.3.76bn740.05m50.01bn18.07k68.2714.2259.2613.319.299.2947.1544.600.74635.785.07207,858.6014.7129.3220.6942.4474.5873.2819.7033.471.26--
Boston Scientific Corporation11.47bn1.10bn54.96bn38.00k50.223.3425.064.790.7680.7688.0111.550.36572.477.02301,842.103.693.034.183.7866.9669.7010.097.171.15--0.35560.00-7.665.80-119.23--0.3484--
DexCom, Inc.2.32bn529.30m57.37bn5.50k111.2826.8592.6024.745.325.3223.2622.040.53882.545.16421,672.7012.305.7814.376.7869.7766.0922.827.984.503.860.45190.0030.5436.81388.23--42.98--
Edwards Lifesciences Corp5.09bn1.48bn68.38bn14.90k46.9312.3442.4313.422.332.338.048.880.6811.648.86341,912.8019.7514.6922.4717.4875.7474.5129.0021.522.87--0.0970.000.880911.96-21.5610.7230.77--
Becton Dickinson and Co20.25bn2.00bn69.61bn75.00k35.792.9416.293.446.856.8569.3683.230.37543.868.27269,960.003.882.614.392.9646.5646.6310.337.490.90137.020.426572.7918.2910.16161.0215.4511.394.69
Stryker Corporation16.67bn1.90bn91.82bn43.00k48.956.4831.945.514.974.9743.6437.590.50181.816.36387,651.205.727.326.638.7262.6565.6911.4013.781.35--0.471539.73-3.587.61-23.242.1312.5210.76
Intuitive Surgical, Inc.5.49bn1.69bn117.53bn8.08k71.0910.3157.6621.414.634.6315.0531.950.46612.728.55679,185.8014.5113.9915.8615.5969.1268.8431.1428.805.01--0.000.00-2.6812.82-23.1112.4933.35--
Medtronic PLC31.80bn4.70bn149.35bn90.00k31.982.8720.074.703.473.4723.4938.660.33892.325.87353,300.005.044.775.655.3667.7168.5114.8814.962.3615.570.329460.934.160.8752-25.94-0.21575.318.83
Abbott Laboratories42.31bn7.27bn222.59bn109.00k31.026.4720.645.264.064.0523.6219.470.59243.507.02388,146.8010.174.1912.184.9156.9057.1117.179.251.4217.260.346978.938.4811.1424.8811.5314.428.45
Thermo Fisher Scientific Inc.39.06bn8.57bn251.69bn80.00k29.636.5022.726.4421.5521.5598.3298.240.56754.386.38488,237.5012.446.4613.857.3151.0546.1521.9314.502.5621.830.35937.9826.1413.6972.1126.3428.377.21
Data as of Nov 26 2021. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

31.53%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2021141.36m7.97%
Capital Research & Management Co. (Global Investors)as of 30 Sep 202184.45m4.76%
BlackRock Fund Advisorsas of 30 Sep 202182.69m4.66%
SSgA Funds Management, Inc.as of 30 Sep 202172.43m4.09%
Capital Research & Management Co. (International Investors)as of 30 Sep 202156.99m3.22%
Geode Capital Management LLCas of 30 Sep 202127.13m1.53%
Massachusetts Financial Services Co.as of 30 Sep 202126.62m1.50%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202125.57m1.44%
Polen Capital Management LLCas of 30 Sep 202122.01m1.24%
BlackRock Investment Management (UK) Ltd.as of 30 Sep 202119.76m1.11%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.